Most known recurrent genomic disorders result from non-allelic homologous recombination (NAHR) or unequal crossing-over between large and highly identical segmental duplications (>10 kb) 1 . Specific human chromosomes (for example, 7, 15, 16, 17 and 22) are enriched for interspersed segmental duplications 2 , and multiple genomic disorders have already been assigned to these 'hot spot' regions of the genome 3,4 . The short arm of chromosome 16 is particularly enriched for large segmental duplications that have arisen specifically during the evolution of humans and great apes [5] [6] [7] [8] . In the last 3 years, at least three microdeletion/microduplication syndromes have been characterized whose breakpoints map within segmental duplications on chromosome 16. These include a 500-kb microdeletion/duplication of 16p11.2 associated with autismspectrum disorders and intellectual disability 9,10 , a large microdeletion encompassing 16p11.2-p12.2 in individuals with a wide spectrum of phenotypic features 11 and distal 16p13.11 rearrangements in individuals with autism, intellectual disability and other neurodevelopmental phenotypes [12] [13] [14] .
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Most known recurrent genomic disorders result from non-allelic homologous recombination (NAHR) or unequal crossing-over between large and highly identical segmental duplications (>10 kb) 1 . Specific human chromosomes (for example, 7, 15, 16, 17 and 22) are enriched for interspersed segmental duplications 2 , and multiple genomic disorders have already been assigned to these 'hot spot' regions of the genome 3, 4 . The short arm of chromosome 16 is particularly enriched for large segmental duplications that have arisen specifically during the evolution of humans and great apes [5] [6] [7] [8] . In the last 3 years, at least three microdeletion/microduplication syndromes have been characterized whose breakpoints map within segmental duplications on chromosome 16 . These include a 500-kb microdeletion/duplication of 16p11.2 associated with autismspectrum disorders and intellectual disability 9, 10 , a large microdeletion encompassing 16p11.2-p12.2 in individuals with a wide spectrum of phenotypic features 11 and distal 16p13.11 rearrangements in individuals with autism, intellectual disability and other neurodevelopmental phenotypes [12] [13] [14] .
We recently performed a genome-wide meta-analysis comparing the frequency of large deletion/duplication events in individuals with neurocognitive or psychiatric disabilities to that in the control population 15 . This meta-analysis pointed towards a potential fourth example of a duplication-mediated microdeletion of ~600 kb on chromosome 16p12.1 that was found in 5 of 6,860 individuals affected by schizophrenia or autism, compared with 0 of 5,674 controls 15 . Therefore, we sought to systematically characterize this particular microdeletion in two large cohorts (discovery set and replication set) of children with intellectual disability (n = 11,873 and 9,254, respectively) compared with controls (n = 8,540 and 6,299, respectively). Our data indicate that the 16p12.1 microdeletion might be a risk factor for neurodevelopmental disease that also acts with other large CNVs to modify neuropsychiatric phenotypes, thereby supporting a 'two-hit' model for the generation of severe cognitive deficits involving this region. Analysis of other microdeletions indicates that this model might help to explain the variability in expressivity of recurrent CNVs associated with neuropsychiatric phenotypes. and 14,839 controls), the pathogenic association of the 16p12.1 microdeletion was highly significant (Fisher's exact test, P = 1.18 × 10 −4 , OR = 3.7; Table 1 ).
We also examined 3,061 individuals who had been diagnosed with schizophrenia and identified three 16p12.1 microdeletions, all in individuals with sporadic schizophrenia (Table 1) . However, we did not observe significant enrichment for the 16p12.1 event specifically in the schizophrenia cases compared to 14,839 total controls (Fisher's exact test, P = 0.29, OR = 1.8), although this might indicate a lack of statistical power in the schizophrenia panel rather than a true lack of disease association (only 3,061 individuals, in contrast to the 21,127 individuals with developmental delay). It is interesting, in this regard, that in one family where both schizophrenia and mental retardation phenotypes were segregating, the 16p12.1 deletion was observed only among individuals diagnosed with both psychosis and severe intellectual disability (see Supplementary Note, family LD1205).
Using high-density and targeted array-based comparative genomic hybridization (CGH) experiments (see Online Methods), we mapped the 16p12.1 microdeletion breakpoints in 37 individuals to two large blocks of segmental duplications ( Fig. 1 and Supplementary Fig. 1 a The 16p12.1 microdeletion was originally identified from a meta-analysis that identified 5 cases from 6,860 individuals with autism, schizophrenia and developmental delay compared to 0 observations in a control group of 5,674 (P = 0.049). None of these cases were used in the discovery set, although the original control group was expanded in the discovery set. b For the replication set, all controls and cases were independent. c Combined set composed of discovery set and replication set.
Within these blocks, we identified a 68-kb duplicon in direct orientation (with 99.5% identity) in relation to its paralog in the distal breakpoint region (Supplementary Table 1 ). As misalignment of directly oriented duplicons during meiosis predisposes to NAHR events resulting in microdeletions 1 , the 68-kb duplicon probably mediates the observed recurrent 16p12.1 rearrangements. Numerous studies of the region using FISH (Fig. 2) , SNP microarrays 16 and sequencingbased approaches 17 reveal that the 68-kb duplicon varies in copy number and that the entire region can be inverted in some individuals, as observed for the 17q21.31 microdeletion 18 . Preliminary analyses suggest that particular structural configurations might be more predisposed to 16p12.1 rearrangement (data not shown). Owing to the complexity at this locus and the high copy-number variation of the duplications, we could not refine the boundary of the breakpoints below 100 kb by array-based CGH. Notably, the microdeletion in one control sample (GAIN_26140) was 102.9 kb shorter in length than those found in affected subjects and did not span the CDR2 gene (encoding cerebellar degeneration related 2) (Fig. 1) .
Phenotypic evaluation and parental analysis
Evaluation of available medical records from the ID/DD cohort showed that multiple phenotypic features are associated with the 16p12.1 microdeletion ( Table 2 and Supplementary Tables 2 and 3) .
Although not all clinical features were completely recognizable in very young subjects, most subjects showed developmental delay and learning disability. All 15 individuals who were older than 12 months had speech delay. Craniofacial and skeletal abnormalities were observed in 22 of 23 cases (Fig. 3) . Growth retardation was documented in 9 of 22 cases and 7 of 20 individuals also had microcephaly ( Table 2) .
(Note that the denominator of these data varies because not all patients could be ascertained for all clinical features.) Furthermore, congenital cardiac disease was observed in 7 of 21 cases, of which four were specifically diagnosed with a hypoplastic left heart syndrome ( Table 2 and Supplementary Table 3 ). Seizure disorders manifesting in various forms, including West syndrome, febrile seizures or seizure-like episodes, were observed in 8 of 22 cases, and hypotonia was present in 10 of 21 cases ( Table 2) . Psychiatric and behavioral abnormalities were also documented in 9 of 16 affected children. Non-typical facial gestalt and variable clinical presentations indicate that this microdeletion is nonsyndromic. Six of twenty individuals with a 16p12.1 microdeletion from the discovery set had an additional chromosomal abnormality or large (>500 kb) CNV (Fig. 4 , Table 3 and Supplementary Table 4 ). The frequency (30%) of such double-hit CNVs was 7.5-fold greater in the cases with 16p12.1 microdeletion (Fisher's exact test, P = 0.0005, OR = 9.7) than in controls conditioned for a large CNV (deletion or duplication) first hit (9 of 217 or 4.1%; Table 3 ). In the replication set, the double-hit frequency was also enriched in affected individuals (4 of 22, 18.2%) compared to controls (12 of 254, 4.7%; Fisher's exact test, P = 0.029, OR = 4.5; Supplementary Table 2 and Supplementary Fig. 2 ). Overall, in the combined set, there was a significant (Fisher's exact test, P = 5.7 × 10 −5 , OR = 6.6) enrichment of double hits among 16p12.1 deletion carriers (10 of 42, 24%) compared to controls (21 of 471, 4.4%; Table 3 ). Significant enrichment for double hits in cases with 16p12.1 microdeletion was also observed when the controls were conditioned to carry only a large deletion event as the first hit (Supplementary Table 5 ).
In the cases where the second-hit CNV is associated with a described syndrome (DECIPHER 19 Figure 2 Genomic structure of 16p12.1 region.
(a) A schematic of the 16p12.1 region shows the location of the microdeletion flanked by directly oriented 68-kb segmental duplication blocks (red boxes). The segmental duplication blocks (red and gray boxes) are connected by green and blue lines to indicate direct or inverted orientation, respectively. Also shown are representative genes in the region with the transcriptional direction. CNP indicates the copy-number polymorphism annotated by SNP genotyping 16 for this region (CNP2157). (b) FISH analysis was performed on lymphoblast cell line from GM18956 using fosmid probes mapping to the 68-kb duplicon (WIBR2-2031K01, shown in red) and the flanking unique regions (WIBR2-3632J22 in green and WIBR2-1829F15 in blue). Results show that the 68-kb duplicon is polymorphic (that is, it has a variable number of copies) and that the orientation of the region is inverted in this HapMap sample compared to the human genome reference assembly. High copy numbers of the segmental duplications have complicated mapping of the inversion breakpoint for this region. 21 and is associated with autism-spectrum disorders 22 , developmental delay, hypotonia, normal to accelerated growth and dysmorphic features including macrocephaly, dolichocephaly and micrognathia. However, SG03 manifests with learning disability, microcephaly, exotropia and periventricular abnormalities, with no autistic features yet apparent (age 2 years 3 months). SG10 carries a 35-Mb deletion on chromosome 5q15q23.2 along with the 16p12.1 microdeletion. Previously, Lindgren and colleagues reported on two individuals carrying a del5q15q23.2 with craniofacial features and benign adenomatous polyps in the intestine 23 . SG10 has developmental delay, significant growth retardation, overt craniofacial features (ptosis, hypertelorism, bifid uvula, exotropia, ectopic pupils, wide nasal bridge and smooth philtrum), hypoactivity and seizures-a more severe phenotype than that reported from a single second hit. Patient SGA2 carries a 1.3-Mb duplication on chromosome 2p13p12 in addition to the 16p12.1 microdeletion and has overt clinical features, including impaired intellectual function, behavior problems, growth anomalies, craniofacial features and café-au-lait spots. Although dup2p13p12 has been reported to be associated with primary cutaneous lymphoma 24 , there have been no reports of developmental defect or craniofacial anomalies. Subject SGA6 carries an 848-kb duplication on chromosome 14q32.1 along with the 16p12.1 microdeletion. Additionally, he has had a mutation identified in the BRAF gene (F468S) that is consistent with a diagnosis of cardiofaciocutaneous syndrome (CFCS). The subject presents with a diverse range of severe clinical features including craniofacial anomalies, complete agenesis of corpus callosum, renal and cardiac defects and Hirschsprung disease (Supplementary Table 3 ). These features are more severe than has been described for CFCS 25 or a de novo dup14q32.1 case reported in association with schizophrenia 26 .
To test whether the subjects inherited the 16p12.1 microdeletion from their parents, we obtained DNA from 23 sets of parents. The 16p12.1 microdeletion was inherited in 22 of 23 cases (17 maternal, 5 paternal), with one case confirmed as being de novo (Fig. 4 and Supplementary Figs. 3 and 4) . Of the seven double-hit cases where inheritance could be assessed, 6 of 7 large CNV second hits were inherited and one large CNV arose de novo. In most cases (5 of 7), either the large CNV second hit was inherited from the parent who did not carry a 16p12.1 microdeletion or it arose de novo. In one case (SG12), a heterozygous dup22q11.21 was transmitted from both parents to the homozygote proband (Fig. 4) . SGA30 inherited both events from the mother (Supplementary Table 6 ).
Parental phenotypic information was obtained during the initial visit before CNV testing from 11 of 13 inherited cases. In two cases, clinical inquiries were made only after the child was found to carry the microdeletion (Supplementary Table 7 ). Carrier parents with the 16p12.1 microdeletion were more likely (P = 0.037, OR = 6, Fisher's exact test) to present with learning disability, depression or bipolar disorders, or seizures than the non-carrier parents (Fig. 4 and Supplementary Table 8 ). We found only three cases (SG11, SGA9 and 25514) in whom the microdeletion was inherited from an apparently normal parent (Supplementary Table 9 ). Compared to the carrier parents, the index cases manifested with more severe, clinically recognizable manifestations, including severe speech and motor disability, recognizable facial dysmorphology and systemic organ abnormalities ( Table 2, Figs. 3 and 4 and Supplementary Note). Finally, we assessed the SNP genotypes for chromosome 16p in 17 probands and 4 available parents to investigate whether there is one specific sequence haplotype that predisposes to this microdeletion. We found that the microdeletion occurred on different haplotype backgrounds, consistent with a recurrent nature for this rearrangement as opposed to inheritance from a common ancestor (Supplementary Note).
DISCUSSION
Previously, we undertook a large meta-analysis study of CNVs in individuals diagnosed with intellectual disability, autism and schizophrenia, identifying the 16p12.1 region as a potential pathogenic locus (five cases and no controls) 15 . However, this study lacked the power to definitively identify a disease association or to delineate the phenotypic consequences of the microdeletion. Here we used the CNV data from one of the largest collections of individuals with intellectual disability and developmental delay to reassess this region. We identified 42 index cases with developmental delay, craniofacial dysmorphology and congenital heart defects and three sporadic and one familial case of overt schizophrenia carrying a similar-sized microdeletion of 16p12.1; we found only eight control individuals carrying a 16p12.1 deletion. Although all cases appear to share the segmental duplication-mediated 520-kb minimal deletion region, it is noteworthy that one deletion-carrying control was retrospectively diagnosed with a major depressive disorder and also had an atypical, smaller deletion (417 kb). Removal of this control sample from our analysis strengthens the association between 16p12.1 microdeletion and disease (Fisher's exact test, P = 4.4 × 10 −5 , OR = 4.2). Comparison to other genomic disorders in our cohort indicates that the incidence of 16p12.1 microdeletion is ~1/15,000 live births, similar to that of Smith-Magenis syndrome (Table 4) . However, the subtle clinical features and variable phenotypes associated with the single 16p12.1 event probably lead to underascertainment or misdiagnoses.
Most of our pediatric cases had indications of developmental delay and learning disability and congenital abnormalities. However, the variable phenotypes associated with the 16p12.1 microdeletion 
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include congenital heart defects, seizures and severe growth abnormalities (Supplementary Note). We also identified five adults with a diagnosis of schizophrenia and found that 23% of the probands inherited the microdeletion from a carrier parent with manifestations of psychiatric disease. Carrier parents were significantly more likely (P = 0.037) to manifest other neurological or neuropsychiatric features (learning disability, depression, bipolar disorders and seizures) than non-carriers. The fact that these parents were recruited as a result of their child's referral constitutes an ascertainment bias; however, any such bias should apply to both parents equally, and yet only 5 of 14 non-carrier parents had any clinical symptoms (Supplementary We used a 135K NimbleGen array to identify these CNVs (with average probe density of 2.5 kb in regions flanked by segmental duplications and an average probe density of 35 kb in the genomic backbone). CNV calls were made using a Hidden Markov Model CNV-calling algorithm described previously 15 .
(e) Pedigrees of individuals with 16p12.1 microdeletions and known available parental information. Circles indicate females; squares indicate males. The intellectual disability and congenital malformation category also includes congenital heart defects and seizures. Psychiatric illness includes depression or bipolar disorder, attention deficit hyperactive disorder and abnormal behavior. Note that there is an excess of transmitting parents with the microdeletion who also manifested a neuropsychiatric phenotype. NT, not tested.
and cognitive phenotypes. In probands carrying the microdeletion, we observed a six-fold excess of double CNV hits (10 of 42, 24%) as compared to normal controls when conditioned for the presence of at least one large CNV (21 of 471, 4%) and a more than 60-fold excess as compared to the general population. Compared to the classical phenotypes associated with the known pathogenic locus, each of these children showed additional or more severe phenotypes (Supplementary Note).
Collectively, these data indicate that phenotypes associated with the 16p12.1 microdeletion show variable expressivity that depends on the genetic background. We conclude that the deletion of 16p12.1 is a significant, independent risk factor for intellectual disability and developmental delay that also acts with other factors to modify neurological phenotypes. We propose a 'two-hit' model, wherein a secondary insult is necessary during development to result in a more severe clinical manifestation of pediatric disease. The second hit could potentially be another CNV, a disruptive single-base-pair mutation in a phenotypically related gene or an environmental event that influences the phenotype. It has been noted that genetic factors that are originally identified to associate with a specific neurological disease are often subsequently identified in individuals with other conditions (for example, del15q13.3 is associated with epilepsy, schizophrenia and intellectual disability) [27] [28] [29] .
The prevalence of schizophrenia in individuals with a learning disability is reported to be three times that of the general population, and several studies indicate that the comorbidity of schizophrenia in learning-disabled individuals is mainly due to a greater tendency for schizophrenic individuals to develop cognitive delay [30] [31] [32] . The observation, in family LD1205, that cognitive impairment is seen only among siblings with the 16p12.1 deletion is also consistent with the hypothesis that the 16p12.1 deletion exacerbates the phenotypic consequences of other heritable neurological disease risk factors within this multiplex family (Supplementary Note). Notably, about 70% of individuals with autism also present with a learning disability 33 . Our 'two-hit' model might also help to explain the significant comorbidity that exists among cognitive impairment, schizophrenia and autism 34 and the underlying phenotypic variability reported for several recurrent microdeletions 29, 35 .
To test this, we investigated the occurrence of two hits more broadly among other genomic disorders. We first reanalyzed the recently reported 1q21.1 microdeletion for the presence of a second large CNV 36 . We found a 40-fold enrichment for two hits (4 of 25, 16%) among cases with 1q21.1 microdeletion when compared to controls. The phenotypes of these four cases were variable, ranging from severe neurological deficit and craniofacial abnormalities to severe schizophrenia without cognitive impairment (Supplementary Note). On the basis of this finding, we expanded our analysis to consider both syndromic and non-syndromic genomic disorders for the frequency of double hits. Our analysis for two hits in nine genomic disorders shows that 16p12.1 microdeletion ranks as the top recurrent CNV that is enriched for the occurrence of two hits (Table 4) . Notably, the proportion of cases with a second hit is generally much higher (9-24% of the cases) for recurrent microdeletions or microduplications where variable expressivity has been reported, including del15q13.3, del16p11.2, dup22q11.2 and del16p12.1. We find an inverse correlation between the proportion of cases that are de novo and the prevalence of the second hit. For example, only one de novo case (~4%) of the 16p12.1 microdeletion has been reported, and this microdeletion shows the greatest fraction of double hits. By contrast, we observed either few or no double hits among canonical syndromes such as Williams and Smith-Magenis syndromes (Table 4) , for which almost all cases arise de novo. We note, however, that we did not find a significant enrichment for two hits among cases with 22q11.2 deletion-similar to that observed by Bassett and colleagues 37 . In general, these findings provide additional support for the two-hit hypothesis, with elevated double-hit rates among pathogenic CNVs with clearly variable penetrance and expressivity. We propose that variable phenotypes of microdeletions such as those at 16p12.1 and 1q21.1 are subject to substantial modification (or that these copy-number variants are themselves modifiers).
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. Accession code. dbGaP (genotype data): GAIN study of schizophrenia (phs000021.v2.p1).
Note: Supplementary information is available on the Nature Genetics website.
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